| European Case Law Identifier: | ECLI:EP:BA:2018:T135112.20180716 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 16 July 2018 | ||||||||
| Case number: | T 1351/12 | ||||||||
| Application number: | 04785793.3 | ||||||||
| IPC class: | C07K 16/00 A61K 39/395 A61P 35/00 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of disease | ||||||||
| Applicant name: | E. R. Squibb & Sons, L.L.C. | ||||||||
| Opponent name: | - | ||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Main request - sufficiency of disclosure Substantial procedural violation - (yes) Remittal to the department of first instance (yes) Reimbursement of appeal fee - (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t121351eu1.html
Date retrieved: 17 May 2021